134 related articles for article (PubMed ID: 17075322)
1. Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction.
Briasoulis E; Karavasilis V; Tzamakou E; Piperidou C; Soulti K; Pavlidis N
Anticancer Drugs; 2006 Nov; 17(10):1219-22. PubMed ID: 17075322
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
4. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Mita AC; Olszanski AJ; Walovitch RC; Perez RP; MacKay K; Tuck DP; Simmons C; Hammond S; Mita MM; Beeram M; Stone AJ; Rowinsky EK; Lewis LD
Clin Cancer Res; 2007 Jun; 13(11):3293-301. PubMed ID: 17545535
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
[TBL] [Abstract][Full Text] [Related]
9. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Drug Metab Dispos; 1999 Nov; 27(11):1300-5. PubMed ID: 10534315
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Siqing F; Culotta KS; Falchook GS; Hong DS; Myers AL; Zhang YP; Naing A; Janku F; Hou MM; Kurzrock R
Cancer Chemother Pharmacol; 2016 Feb; 77(2):357-64. PubMed ID: 26698868
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
Camacho LH; Kurzrock R; Cheung A; Barber DF; Gupta S; Madoff DC; Wallace MJ; Kim EE; Curley SA; Hortobagyi GN; Mavligit G
Cancer; 2007 Jun; 109(11):2190-6. PubMed ID: 17464952
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
15. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
16. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Panday VR; Huizing MT; Willemse PH; De Graeff A; ten Bokkel Huinink WW; Vermorken JB; Beijnen JH
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-34-S11-38. PubMed ID: 9314297
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]